Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders.
Adolescent
Adult
Aged
Biopsy
Child
Child, Preschool
Cohort Studies
Colitis
/ pathology
Colon
/ pathology
Endoscopy, Gastrointestinal
Enteritis
/ pathology
Eosinophilia
/ pathology
Eosinophils
/ pathology
Erythema
/ pathology
Female
Gastritis
/ pathology
Humans
Infant
Intestine, Small
/ pathology
Leukocyte Count
Male
Middle Aged
Retrospective Studies
Stomach
/ pathology
Ulcer
/ pathology
Young Adult
Eosinophilic colitis
Eosinophilic esophagitis
Eosinophilic gastritis
Eosinophilic gastroenteritis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
08
2019
accepted:
13
11
2019
pubmed:
28
11
2019
medline:
11
11
2020
entrez:
28
11
2019
Statut:
ppublish
Résumé
Little is known about the endoscopic and histologic findings of non-esophageal eosinophilic gastrointestinal diseases (EGID). To characterize the presenting endoscopic and histologic findings in patients with eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC) at diagnosis and 6 months after initiating the treatment. We conducted a retrospective cohort study at 6 US centers associated with the Consortium of Eosinophilic Gastrointestinal Researchers. Data abstracted included demographics, endoscopic findings, tissue eosinophil counts, and associated histologic findings at diagnosis and, when available, after initial treatment. Of 373 subjects (317 children and 56 adults), 142 had EG, 123 EGE, and 108 EC. Normal endoscopic appearance was the most common finding across all EGIDs (62% of subjects). Baseline tissue eosinophil counts were quantified in 105 (74%) EG, 36 (29%) EGE, and 80 (74%) EC subjects. The mean peak gastric eosinophil count across all sites was 87 eos/hpf for EG and 78 eos/hpf for EGE. The mean peak colonic eosinophil count for EC subjects was 76 eos/hpf (range 10-500). Of the 29% of subjects with post-treatment follow-up, most had an improvement in clinical, endoscopic, and histologic findings regardless of treatment utilized. Reductions in tissue eosinophilia correlated with improvements in clinical symptoms as well as endoscopic and histologic findings. In this large cohort, normal appearance was the most common endoscopic finding, emphasizing the importance of biopsy, regardless of endoscopic appearance. Decreased tissue eosinophilia was associated with improvement in symptoms, endoscopic, and histologic findings, showing that disease activity is reversible.
Sections du résumé
BACKGROUND
Little is known about the endoscopic and histologic findings of non-esophageal eosinophilic gastrointestinal diseases (EGID).
AIM
To characterize the presenting endoscopic and histologic findings in patients with eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC) at diagnosis and 6 months after initiating the treatment.
METHODS
We conducted a retrospective cohort study at 6 US centers associated with the Consortium of Eosinophilic Gastrointestinal Researchers. Data abstracted included demographics, endoscopic findings, tissue eosinophil counts, and associated histologic findings at diagnosis and, when available, after initial treatment.
RESULTS
Of 373 subjects (317 children and 56 adults), 142 had EG, 123 EGE, and 108 EC. Normal endoscopic appearance was the most common finding across all EGIDs (62% of subjects). Baseline tissue eosinophil counts were quantified in 105 (74%) EG, 36 (29%) EGE, and 80 (74%) EC subjects. The mean peak gastric eosinophil count across all sites was 87 eos/hpf for EG and 78 eos/hpf for EGE. The mean peak colonic eosinophil count for EC subjects was 76 eos/hpf (range 10-500). Of the 29% of subjects with post-treatment follow-up, most had an improvement in clinical, endoscopic, and histologic findings regardless of treatment utilized. Reductions in tissue eosinophilia correlated with improvements in clinical symptoms as well as endoscopic and histologic findings.
CONCLUSIONS
In this large cohort, normal appearance was the most common endoscopic finding, emphasizing the importance of biopsy, regardless of endoscopic appearance. Decreased tissue eosinophilia was associated with improvement in symptoms, endoscopic, and histologic findings, showing that disease activity is reversible.
Identifiants
pubmed: 31773359
doi: 10.1007/s10620-019-05961-4
pii: 10.1007/s10620-019-05961-4
pmc: PMC7315780
mid: NIHMS1596547
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2024-2035Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007634
Pays : United States
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI117804
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Gut Liver. 2018 May 15;12(3):288-296
pubmed: 29212311
Transl Sci Rare Dis. 2017 Dec 18;2(3-4):141-155
pubmed: 29333363
Mod Pathol. 2015 Mar;28(3):383-90
pubmed: 25216228
Curr Opin Gastroenterol. 2013 Jan;29(1):7-14
pubmed: 23132211
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1733-1741
pubmed: 28603057
Pediatr Dev Pathol. 2006 May-Jun;9(3):210-8
pubmed: 16944979
Gastroenterol Clin North Am. 2014 Jun;43(2):257-68
pubmed: 24813514
Mod Pathol. 2011 Apr;24(4):556-63
pubmed: 21169993
Front Med (Lausanne). 2018 Jan 15;4:261
pubmed: 29379785
Intern Med. 2019 Aug 1;58(15):2167-2171
pubmed: 30996166
J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):36-42
pubmed: 25988554
J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):175-82
pubmed: 20890222
Clin Gastroenterol Hepatol. 2012 Sep;10(9):988-96.e5
pubmed: 22610003
Am J Gastroenterol. 2014 Aug;109(8):1277-85
pubmed: 24957155
Dig Liver Dis. 2015 Mar;47(3):197-201
pubmed: 25547198
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1842-1844
pubmed: 27112108
Dig Dis Sci. 2019 Aug;64(8):2231-2241
pubmed: 30982212
Virchows Arch. 2018 Sep;473(3):313-320
pubmed: 29987614
Aliment Pharmacol Ther. 2018 Apr;47(8):1143-1150
pubmed: 29488232
Am J Surg Pathol. 2017 Nov;41(11):1491-1498
pubmed: 28863076
Immunol Allergy Clin North Am. 2007 Aug;27(3):443-55
pubmed: 17868858
Scand J Gastroenterol. 2011 Sep;46(9):1074-80
pubmed: 21623674
Am J Gastroenterol. 2019 Jun;114(6):984-994
pubmed: 31008735
Pediatr Dev Pathol. 2011 Jul-Aug;14(4):294-300
pubmed: 21341989
Hum Pathol. 2016 Aug;54:55-63
pubmed: 27045513
Gastrointest Endosc Clin N Am. 2018 Jan;28(1):15-25
pubmed: 29129296